Assembly Biosciences Inc (ASMB)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Assembly Biosciences Inc (ASMB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011824
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Assembly Biosciences Inc (Assembly), formerly Ventrus Biosciences Inc is a biotechnology company that discover, develops and commercializes small molecule therapies. The company develops therapies for the treatment of infectious diseases such as chronic hepatitis B virus (HBV) and microbiotic therapies for Clostridium difficile (C. difficile) infections (CDI). It also develops Gemicel platform technology that helps for targeted oral delivery vaccines, live biotherapeutics, small molecules and complex macromolecules which are aimed for specific region in gastrointestinal tract(GI). Assembly’s HBV Cure program target’s the chronic hepatitis B virus infection. The company has research and development facilities in New York, Indiana and California. Assembly is headquartered in Carmel, Indiana, the US.

Assembly Biosciences Inc (ASMB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Assembly Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Ventrus Biosciences Acquires Rights To Iferanserin From Sam Amer For US$23 Million 10
Merger 11
Ventrus Biosciences Completes Merger with Assembly Pharma 11
Licensing Agreements 12
Allergan Enters into Licensing Agreement with Assembly Biosciences 12
Ventrus Biosciences Enters into Licensing Agreement with Therabiome 14
Assembly Biosciences Enters Into Licensing Agreement with Indiana University Research and Technology 15
Assembly Pharma Enters into Licensing Agreement with IURTC 16
Equity Offering 17
Assembly Biosciences Prices Public Offering of Shares for USD60.2 Million 17
Assembly Biosciences Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 18
Assembly Biosciences Raises USD15.8 million in Private Placement of Shares 20
Ventrus Biosciences Announces Public Offering Of Shares For US$20.5 Million 21
Ventrus Biosciences Completes Underwriters’ Exercise Of Over-Allotment Option For Public Offering Of Shares For US$16.7 Million 22
Ventrus Biosciences Completes Public Offering Of Preferred Shares For US$5.5 Million 24
Ventrus Biosciences Completes An Underwritten Public Offering For US$51.8 Million 25
Ventrus Biosciences Completes IPO For US$20 Million 27
Assembly Biosciences Inc – Key Competitors 29
Assembly Biosciences Inc – Key Employees 30
Assembly Biosciences Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Corporate Communications 32
Jul 28, 2017: Assembly Biosciences Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 32
Jan 11, 2016: Assembly Biosciences Expands Senior Leadership Team 33
Product News 35
01/27/2016: Assembly Biosciences Presents Clinical Data at Drug Formulation & Bioavailability Summit Showing Its Oral Gemicel Technology Achieves Targeted Delivery to the Lower GI Tract 35
Clinical Trials 36
Sep 25, 2017: Assembly Biosciences Selects Next-Generation CpAM Candidate for Advancement into Clinical Development 36
Nov 09, 2016: Assembly Biosciences Initiates Phase 1 Clinical Program of ABI-H0731 for Treatment of Chronic Hepatitis B Virus Infection 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Assembly Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Assembly Biosciences Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Ventrus Biosciences Acquires Rights To Iferanserin From Sam Amer For US$23 Million 10
Ventrus Biosciences Completes Merger with Assembly Pharma 11
Allergan Enters into Licensing Agreement with Assembly Biosciences 12
Ventrus Biosciences Enters into Licensing Agreement with Therabiome 14
Assembly Biosciences Enters Into Licensing Agreement with Indiana University Research and Technology 15
Assembly Pharma Enters into Licensing Agreement with IURTC 16
Assembly Biosciences Prices Public Offering of Shares for USD60.2 Million 17
Assembly Biosciences Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 18
Assembly Biosciences Raises USD15.8 million in Private Placement of Shares 20
Ventrus Biosciences Announces Public Offering Of Shares For US$20.5 Million 21
Ventrus Biosciences Completes Underwriters' Exercise Of Over-Allotment Option For Public Offering Of Shares For US$16.7 Million 22
Ventrus Biosciences Completes Public Offering Of Preferred Shares For US$5.5 Million 24
Ventrus Biosciences Completes An Underwritten Public Offering For US$51.8 Million 25
Ventrus Biosciences Completes IPO For US$20 Million 27
Assembly Biosciences Inc, Key Competitors 29
Assembly Biosciences Inc, Key Employees 30
Assembly Biosciences Inc, Other Locations 31
Assembly Biosciences Inc, Subsidiaries 31

★海外企業調査レポート[Assembly Biosciences Inc (ASMB)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Orascom Construction Ltd (OC):企業の財務・戦略的SWOT分析
    Summary Orascom Construction Ltd (Orascom Construction) is an engineering and construction contracting company which concentrates on large industrial, commercial and infrastructure projects. The company offers services, which include civil engineering works, buildings construction and industrial com …
  • Ion Beam Applications SA (IBAB):企業の財務・戦略的SWOT分析
    Ion Beam Applications SA (IBAB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Arena Pharmaceuticals Inc (ARNA):製薬・医療:M&Aディール及び事業提携情報
    Summary Arena Pharmaceuticals Inc (Arena) is a biopharmaceutical company which discovers, develops and commercializes small molecule drugs in multiple therapy areas. It is evaluating its lead candidate etrasimod for multiple inflammatory indications including ulcerative colitis, primary biliary chol …
  • Caterpillar Inc.:企業の戦略・SWOT・財務情報
    Caterpillar Inc. - Strategy, SWOT and Corporate Finance Report Summary Caterpillar Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Jefferies Group LLC:企業の戦略・SWOT・財務情報
    Jefferies Group LLC - Strategy, SWOT and Corporate Finance Report Summary Jefferies Group LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • The J. R. Simplot Co:企業の戦略・SWOT・財務情報
    The J. R. Simplot Co - Strategy, SWOT and Corporate Finance Report Summary The J. R. Simplot Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • JinkoSolar Holding Co Ltd (JKS):電力:M&Aディール及び事業提携情報
    Summary JinkoSolar Holding Co Ltd (JinkoSolar) is a manufacturer of solar products. The company is involved in manufacturing and marketing of solar power products such as silicon ingots, silicon wafers, solar modules, solar PV cells, and monocrystalline and multicrystalline photovoltaic (PV) panels. …
  • Lipocine Inc (LPCN):企業の財務・戦略的SWOT分析
    Summary Lipocine Inc (Lipocine) operates as a pharmaceutical company that develops and commercializes treatment for men's and women's health. The company’s pipeline products for men’s health include LPCN 1111 and LPCN 1021; and for women’s health include LPCN 1107. Its LPCN 1111 is an oral testoster …
  • British Columbia Cancer Agency:医療機器:M&Aディール及び事業提携情報
    Summary British Columbia Cancer Agency (BC Cancer Agency), a subsidiary of Provincial Health Services Authority is a healthcare service center that provides comprehensive cancer control program. The center offers services such as diagnostic and therapy planning, radiation therapy, patient assessment …
  • Intas Pharmaceuticals Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Intas Pharmaceuticals Ltd (Intas) develops, manufactures, and markets pharmaceuticals and biotechnology products for the treatment of a wide range of diseases and disorders in various therapeutic segments. The company offers products such as sevelamer, ciprofloxacin, amitryptyline, erythropo …
  • Konica Minolta Medical Imaging USA Inc:医療機器:M&Aディール及び事業提携情報
    Summary Konica Minolta Medical Imaging USA Inc (KMMI), a subsidiary of Konica Minolta Inc is a medical device company that manufactures and distributes digital and traditional imaging products. The company provides comprehensive imaging solutions including, digital radiography, ultrasound, healthcar …
  • SK Holdings Co Ltd (034730):企業の財務・戦略的SWOT分析
    SK Holdings Co Ltd (034730) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Carnarvon Petroleum Ltd Oil & Gas Exploration and Production Operations and Cost Analysis – 2017
    Carnarvon Petroleum Ltd Oil & Gas Exploration and Production Operations and Cost Analysis - 2017 Summary Carnarvon Petroleum Ltd Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive inform …
  • Crown Point Energy Inc (CWV):石油・ガス:M&Aディール及び事業提携情報
    Summary Crown Point Energy Inc (Crown Point), formerly Crown Point Ventures is an oil and gas company that offers oil and gas development and exploration services. The company acquires and produces crude oil and natural gas deposits. It holds interests in Cerro de Los Leones exploration concessions …
  • Apache Corp (APA):企業の財務・戦略的SWOT分析
    Apache Corp (APA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Imperial Oil Ltd (IMO):石油・ガス:M&Aディール及び事業提携情報
    Summary Imperial Oil Ltd (Imperial Oil), a subsidiary of Exxon Mobil Corporation, is an integrated energy company. It is present across the value chain in petroleum industry including the exploration, production and sale of crude oil and natural gas. The company explores for and produces crude oil, …
  • PriceSmart, Inc.:企業の戦略・SWOT・財務情報
    PriceSmart, Inc. - Strategy, SWOT and Corporate Finance Report Summary PriceSmart, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Duke Energy Carolinas LLC:発電所・企業SWOT分析
    Duke Energy Carolinas LLC – Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key emp …
  • BioMarker Strategies LLC-医療機器分野:企業M&A・提携分析
    Summary BioMarker Strategies LLC (BioMarker Strategies) is a biotechnology company that develops tissue-based cancer diagnostic systems. The company offers cancer diagnostics system for predictive tests to targeted treatments for solid tumor malignancies. It also offers pathmap functional signaling …
  • Enbridge Energy Partners LP (EEP):電力:M&Aディール及び事業提携情報
    Summary Enbridge Energy Partners LP (EEP) is a midstream energy partnership that owns and operates a diversified portfolio of crude oil and liquids transportation systems in the US. It provides services through interstate pipeline transportation and storage of crude oil and liquid petroleum. The par …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆